Search - tctmd.com

Displaying 41 - 60 of 167

Sort: Relevancy | Date

Presentation NY Valves 2024

Myosin Inhibitors and Novel Medical Therapies for HCM

Presenter: Mark V. Sherrid

June 07, 2024

Presentation NY Valves 2024

The SESAME Procedure for Obstructive HCM.

Presenter: Jaffar M. Khan

June 07, 2024

Presentation NY Valves 2024

A Clinical Approach to Genetics in Hypertrophic Cardiomyopathy

Presenter: Martin Maron

June 07, 2024

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

News Daily News

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

Yael L. Maxwell

May 08, 2024

News Conference News ACC 2024

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Caitlin E. Cox

April 15, 2024

News Conference News EHRA 2024

Ultralow-Temperature Cryoablation Promising for Monomorphic VT

Todd Neale

April 12, 2024

Presentation ACC 2024

Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (Results of IMPROVE-HCM)

Presenter: Martin S. Maron

April 08, 2024

Presentation THT 2024

Initial Experience with Transcatheter Myotomy (SESAME) to Treat Hypertrophic Cardiomyopathy and Left Ventricular Outflow Obstruction

Presenter: Adam B. Greenbaum

March 05, 2024

Presentation THT 2024

Transcather Approaches to HOCM: From ASA to SESAME

Presenter: Adam B. Greenbaum

March 04, 2024

Presentation THT 2024

Surgical Management of HOCM

Presenter: Hiroo Takayama

March 04, 2024

Presentation THT 2024

Cardiac Myosin Inhibitors as a Novel Treatment Option for Nonobstructive Hypertrophic Cardiomyopathy

Presenter: Ahmad Masri

March 04, 2024

Presentation THT 2024

HCM Genetics- Prognostic/Therapeutic Implications and Counseling

Presenter: Carolyn Ho

March 04, 2024

Presentation THT 2024

Multimodality Imaging to Phenotype HCM

Presenter: Martin Maron

March 04, 2024

Presentation THT 2024

KEYNOTE: The Spectrum of HCM – Lessons From a Half-Century Journey

Presenter: Christine Seidman

March 04, 2024

News Daily News

Top Heart Failure News of 2023

Shelley Wood

January 05, 2024

News Daily News

Aficamten Delivers Positive Results in SEQUOIA-HCM

Todd Neale

December 27, 2023

News Features

FDA Clears AI-ECG Screening Tools for CV Care: What’s Next Is Up for Grabs

Yael L. Maxwell

December 14, 2023

News Conference News AHA 2023

Coincidental Nonischemic Cardiomyopathy Impacts Prognosis in CAD

Todd Neale

November 09, 2023

Presentation TCT 2023

TCT 528: Procedural Complications and Outcomes in Patients with Hypertrophic Obstructive Cardiomyopathy Undergoing Septal Myomectomy Versus Alcohol Septal Ablation.

Presenter: Ndausung Udongwo

October 26, 2023

Advertisement

Myosin Inhibitors and Novel Medical Therapies for HCM

The SESAME Procedure for Obstructive HCM.

A Clinical Approach to Genetics in Hypertrophic Cardiomyopathy

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

New HCM Guidelines Focus on Cardiac Myosin Inhibitors and Exercise

IMPROVE-HCM: Ninerafaxstat May Fill a Niche in Nonobstructive HCM

Ultralow-Temperature Cryoablation Promising for Monomorphic VT

Efficacy and Safety of Ninerafaxstat, a Novel Cardiac Mitotrope, in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy (Results of IMPROVE-HCM)

Initial Experience with Transcatheter Myotomy (SESAME) to Treat Hypertrophic Cardiomyopathy and Left Ventricular Outflow Obstruction

Transcather Approaches to HOCM: From ASA to SESAME

Surgical Management of HOCM

Cardiac Myosin Inhibitors as a Novel Treatment Option for Nonobstructive Hypertrophic Cardiomyopathy

HCM Genetics- Prognostic/Therapeutic Implications and Counseling

Multimodality Imaging to Phenotype HCM

KEYNOTE: The Spectrum of HCM – Lessons From a Half-Century Journey

Top Heart Failure News of 2023

Aficamten Delivers Positive Results in SEQUOIA-HCM

FDA Clears AI-ECG Screening Tools for CV Care: What’s Next Is Up for Grabs

Coincidental Nonischemic Cardiomyopathy Impacts Prognosis in CAD

TCT 528: Procedural Complications and Outcomes in Patients with Hypertrophic Obstructive Cardiomyopathy Undergoing Septal Myomectomy Versus Alcohol Septal Ablation.

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content